Delivery Order SPE2DB22D2007-SPE2DB25FJ1PM

Award Date 5/16/25
Potential Completion Date 5/19/25
Potential Value $1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $10,326.08, is for the delivery of 4,568,142,317 units of the diabetes medication Glimepiride 2 mg tablets. The contract has a period of performance through May 6, 2025 and does not utilize any set-aside designations, indicating open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the purchase of GLIMEPIRIDE 2 MG TABLET 100S. The contract has a ceiling value of $1,226.55 and runs through May 6, 2024. The award is not associated with a set-aside program. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that provides medical products and prescription drugs to federal government agencies, with a significant focus on supporting military...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Glimepiride 2 mg tablets, a medication used to treat type 2 diabetes. The contract has a ceiling value of $1,451.32 and a period of performance through April 28, 2025. It is a firm fixed-price contract, with no set-aside designation, indicating open competition. AmerisourceBergen...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Glimepiride 2 mg tablets, a prescription medication used to treat type 2 diabetes. The fixed-price contract has a ceiling value of $18,382.09 and a period of performance through January 5, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between...
This is a Delivery Order award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999. The award is for the supply of GLIMEPIRIDE 4 MG TABLET 100S, a generic diabetes medication, with a ceiling value of $2,077.56 and a period of performance through March 2025. The contract has no set-aside designation, indicating open competition. This IDC serves as a primary vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,604.97 firm fixed-price contract is for the delivery of 4,566,149,248 units of the generic medication glimepiride 2 mg tablets. The contract has an ultimate completion date of October 21, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,568,143,237 units of the diabetes medication Glimepiride 4 mg tablets. The delivery order, valued at $5,993.70, is a firm fixed-price contract with a completion date of May 6, 2025. AmerisourceBergen Drug Corp is the prime contractor, and there is no set-aside designation, indicating open competition. The contract is part of a larger...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,690.42 firm fixed-price delivery order covers the supply of 4 mg Glimepiride tablets, a medication used to treat diabetes. The contract has an ultimate completion date of December 23, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has a ceiling value of $3,342.87 and an ultimate completion date of April 30, 2025. The contract is for the supply of 4,568,076,664 tablets of the diabetes medication Glimepiride 1 mg. No set-aside designation is mentioned, indicating this was an open competition. AmerisourceBergen Drug Corp holds a larger $999,999,999.00...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,826.50 firm fixed-price delivery order contract is for the supply of GLIMEPIRIDE 4 MG TABLET 100S, a medication used for the treatment of diabetes. The contract has an ultimate completion date of March 10, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB25FJ1PM
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GLIMEPIRIDE 2 MG TABLET 100S, a diabetes medication, with a firm fixed price of $1,044.44 and a performance period ending on May 19, 2025.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This delivery order is issued under that larger IDC contract, allowing the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The contract is not designated as a set-aside.

Generated 8/15/25, 9:59 AM